Myriad Genetics, Inc. (MYGN)

Fisher Asset Management LLC lifted its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 20.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,294,822 shares of the company's stock after acquiring an additional 219,607 shares

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

Acadian Asset Management LLC bought a new position in Myriad Genetics, Inc. (NASDAQ: MYGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 969,127 shares of the company's stock, valued at approximately $5,139,000. Acadian Asset Management LLC owned about

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until mid-to-late 2026.

Myriad Genetics (MYGN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.

Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expectations . Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.

Cwm LLC lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 148.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,327 shares of the company's stock after acquiring an additional 14,531 shares during the

Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company's quarterly earnings will be released the same day after the market closes.

The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations

Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A new nationwide survey from Myriad Genetics shows many women fear cancer screenings—yet most say genetic testing would actually give them peace of mind. During a recent satellite media tour in partnership with Myriad Genetics and D S Simon Media, OB-GYN Dr. Ifeyinwa Stitt and patient with hereditary cancer risk Jodi Lavery discussed how to overcome the fear of screenings, the importance of knowing your cancer family health history, and how genetic testing for hereditary cancer risk can empower women with knowledge that helps them take control of their health.

SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.